We use cookies to improve your browsing experience on our website.
Please visit our Privacy Notice for more information about cookies and how we use them. We recommend that you accept the use of cookies for better navigation.

Newsroom

Show
October 09, 2019
Publication on Efficacy of PREVENA™ Therapy in Reducing Postsurgical Wound Complications Awarded European Paper of the Year
prevena

Study honored by Plastic and Reconstructive Surgery – Global Open at Plastic Surgery the Meeting

SAN ANTONIO – KCI, an Acelity Company, today announced that a paper highlighting results from a study demonstrating the efficacy of PREVENA™ Incision Management System in reducing postsurgical wound complications in patients recovering from oncological breast surgery has been awarded the “Best European Paper” in the Best Papers 2019 awards from Plastic and Reconstruction Surgery – Global Open (PRS GO). The award was presented during Plastic Surgery the Meeting in San Diego on September 22, 2019. 

 

The paper, “Closed Incision Negative Pressure Therapy in Oncological Breast Surgery: Comparison with Standard Care Dressings,” established that patients in the PREVENA™ Therapy group showed significantly lower postsurgical complication rates, with 4 percent in the PREVENA™ Therapy group versus 45 percent in the conventional post-surgery dressing (standard of care (SOC)) group.1

 

“The gathering of compelling clinical evidence is critical in supporting our commitment to expanding access to clinicians and their patients on a global scale, as it allows us to demonstrate efficacy and reinforce the importance of these therapies in markets where there are unmet needs,” said Ronald Silverman, MD, FACS, Chief Medical Officer, KCI. “The data on PREVENA™ Therapy is unsurpassed when it comes to closed incision negative pressure wound therapy devices, and this honor underscores the impact clinical evidence can have on postsurgical care moving forward.” 

 

“My experience with KCI was tremendously eye-opening and I learned new things every day,” said Alex Valdez, product marketing intern, KCI. “It was very encouraging to be surrounded by people who are clearly passionate about their work and who looked to support me in my professional growth.”

 

“The data on PREVENA™ Therapy has shown its ability to help reduce postsurgical complications and give my patients some peace of mind during their recovery and I am honored to have received this award,” said Pietro Ferrando, MD, PhD, Plastic Surgery Department, Città della Salute e della Scienza, C.T.O. Hospital, Turin, Italy. “Breast cancer surgery is very emotional for patients and complex surgery for surgeons. I look forward to continuing to see the impact PREVENA™ Therapy has on my practice and beyond.”

 

The PRS GO Best Paper Awards are given out each year based on data collected from all manuscripts published in that calendar year, scored based on pre-set criteria independent of publication month and selected within pre-existing categories. 

 

Study Overview
“Closed Incision Negative Pressure Therapy in Oncological Breast Surgery: Comparison with Standard Care Dressings:” 

  • In a study of 37 patients undergoing oncological breast surgery, 17 patients (25 surgeries) received ciNPT with the PREVENA™ Incision Management System and the remaining 20 patients (20 surgeries) had SOC. 
  • The study was originally published in Plastic and Reconstructive Surgery – Global Open in June 2018.  

 

About PREVENA™ Incision Management System
The PREVENA™ System, launched in 2010, is the first disposable negative pressure system designed specifically for the management of closed surgical incisions. The system covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision. Please refer to the Instructions for Use for the PREVENA™ Systems for a complete list of appropriate uses, warnings, and precautions. 

About KCI, an Acelity Company
KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing. Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.


References

1. Ferrando PM, Ala A, Bussone R, Bergamasco L, Perinetti FA, Malan F. Closed incision negative pressure therapy in oncological breast surgery: Comparison with standard care dressings. Plast Reconstr Surg Glob Open. 2018;6(6):e1732.


 

Maggie Fairchild
Corporate Communications
Phone: +1-210-330-2666
Email: maggie.fairchild@acelity.com